Penn Capital Management’s TG Therapeutics TGTX Stock Holding History

Penn Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18M	Buy	541,960 +3,843	+0.7%	+$115K	1.4%	20
2025 Q4	$16.1M	Buy	538,117 +16,857	+3%	+$551K	1.28%	29
2025 Q3	$18.9M	Buy	521,260 +77,895	+18%	+$2.57M	1.45%	12
2025 Q2	$16M	Buy	443,365 +51,183	+13%	+$1.91M	1.38%	26
2025 Q1	$15.5M	Buy	392,182 +40,774	+12%	+$1.37M	1.51%	19
2024 Q4	$10.6M	Buy	+351,408	New	+$10.1M	1.04%	52

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Penn Capital Management's TGTX Position: Q1 2026 in Review

Penn Capital Management increased its TG Therapeutics (TGTX) stake by 0.71% in Q1 2026, buying an estimated $115K and bringing the position to 541,960 shares worth $18M. The position accounts for 1.4% of the portfolio, ranked #20.

Penn Capital Management first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $18.9M in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Penn Capital Management held 541,960 shares of TG Therapeutics worth $18M as of Q1 2026.
Penn Capital Management bought 3,843 TG Therapeutics shares in Q1 2026, an estimated $115K.
TG Therapeutics made up 1.4% of Penn Capital Management's portfolio in Q1 2026, its #20 holding.
Penn Capital Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
Penn Capital Management's TG Therapeutics position peaked at $18.9M in Q3 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.